NATCOPHARM — Natco Pharma Share News
0.000.00%
Last trade - 00:00- IN₹141.83bn
- IN₹120.26bn
- IN₹40.78bn
India's Natco Pharma up as FDA's inspection ends with zero observations
Brief: Natco Pharma Completed USFDA Inspection Of Co’S Compliance To Pharmacovigilance Requirements
Brief: Natco Pharma Announces Completion Of Inspection By USFDA For Pharma Division Located In Kothur Hyderabad, India
India's Natco Pharma falls after co named among defendants in antitrust lawsuit in US
Brief: Natco Pharma Says Celgene Corp, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc. And Co Named Defendants In An Antitrust Lawsuit In US
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Brief: Natco Pharma Invests $2 Million In Isca Inc
Brief: Natco Pharma June-Quarter Consol Net Profit Rises
Brief: Natco Pharma Says Co Files Generic Erdafitinib Tablets In Usa
Brief: Natco Pharma Gets Final Approval For ANDA For Tipiracil Hydrochloride And Trifluridine
Brief: Natco Pharma Received Establishment Inspection Report From The USFDA For Its Facility At Visakhapatnam, Andhra Pradesh
Brief: India's Natco Pharma Reports Profit For March-Qtr
Brief: Natco Pharma Approves To Incorporate A Subsidiary Company In Indonesia
Brief: Natco Pharma Announces Launch Of Additional Strengths For Generic Version Of Revlimid In Usa
Brief: Teva And Natco Announce Launch Of Additional Strengths For The Generic Version Of Revlimid® (Lenalidomide Capsules), In The U.S.
Brief: Natco Pharma Approved Buyback Of Shares Worth Upto 2.1 Bln Rupees
India's Natco Pharma rises most in over 5 mths after share buyback plan
Brief: Natco Pharma To Consider A Proposal For Share Buyback
Brief: Natco Pharma - Launches Generic Pomalidomide Capsules In Canada